References
- Schrappe M. Minimal residual disease: optimal methods, timing, and clinical relevance for an individual patient. Hematology Am Soc Hematol Educ Program 2012:137–42.
- Pérez-Galán P, Dreyling M, Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 2011;117:26–38.
- Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007;7:750–762.
- Kienle D, Kröber A, Katzenberger T, et al. VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome. Blood 2003;102:3003–3009.
- Ek S, Dictor M, Jerkeman M, et al. Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma. Blood 2008;111:800–805.
- Mozos A, Royo C, Hartmann E, et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica 2009;94:1555–1562.
- Hamborg KH, Bentzen HHN, Grubach L, et al. A highly sensitive and specific qPCR assay for quantification of the biomarker SOX11 in mantle cell lymphoma. Eur J Haematol 2012;89:385–394.
- Simonsen AT, Sørensen CD, Ebbesen LH, et al. SOX11 as a minimal residual disease marker for mantle cell lymphoma. Leuk Res 2014;38:918–924.
- Brizova H, Kalinova M, Krskova L, et al. Quantitative monitoring of cyclin D1 expression: a molecular marker for minimal residual disease monitoring and a predictor of the disease outcome in patients with mantle cell lymphoma. Int J Cancer 2008;123:2865–2870.
- Andersen NS, Donovan JW, Zuckerman A, et al. Real-time polymerase chain reaction estimation of bone marrow tumor burden using clonal immunoglobulin heavy chain gene and bcl-1/JH rearrangements in mantle cell lymphoma. Exp Hematol 2002;30: 703–710.
- Sørensen CD, Jørgensen JM, Nederby L, et al. Common consensus LNA probe for quantitative PCR assays in cancer: vehicles for minimal residual disease detection in t(11;14) and t(14;18) positive malignant lymphomas. J Immunol Methods 2014;406:131–136.
- Meggendorfer M, Kern W, Haferlach C, et al. SOX11 overexpression is a specific marker for mantle cell lymphoma and correlates with t(11;14) translocation, CCND1 expression and an adverse prognosis. Leukemia 2013;27:2388–2391.
- Moravcová J, Nádvorníková S, Sieglová Z, et al. Do transcriptionally silent BCR-ABL cells persist in CML patients in molecular remission after stem cell transplantation? Leukemia 2001;15:997–999.
- Andersen NS, Pedersen LB, Laurell A, et al. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J Clin Oncol 2009;27:4365–4370.
- Pott C, Hoster E, Delfau-Larue M-H, et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood 2010;115:3215–3223.
- Dreyling M, Thieblemont C, Gallamini A, et al. ESMO consensus conferences: guidelines on malignant lymphoma. Part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol 2013;24:857–877.
- Bacher U, Kern W, Haferlach C, et al. Cyclin D1 (CCND1) messenger RNA expression as assessed by real-time PCR contributes to diagnosis and follow-up control in patients with mantle cell lymphoma. Exp Hematol 2013;41:1028–1037.